Rohit R. Arora, MD, FACC, FAHA, FACP, FSCAI
Professor of Medicine
Professor of Physiology and Biophysics
Chairman of Cardiology
Vice Chairman of Medicine
The Chicago Medical School
North Chicago, IL
Manju T. Beier, PharmD, CGP, FASCP
Senior Partner, Geriatric Consultant Resources LLC
Adjunct Clinical Associate Professor of Pharmacy
The University of Michigan
Ann Arbor, MI
1.25 hours (0.125 CEU)
Link - Online
NOTE: This activity was presented on November 16, 2011, in conjunction with ASCP's Annual Meeting and Exhibition. Participants who received credit for attending the live presentation on that date are not eligible to receive credit for this online activity.
Approximately 2.2 million people in the United States have been diagnosed with atrial fibrillation (AF), the most common cardiac arrhythmia, and the risk of stroke in these patients is substantial. Patients with AF have a fivefold increased risk for stroke. In older adults, AF leads to 25% of all strokes, and stroke is the leading cause of long-term disability and the third-leading cause of death in the United States. Because of the rapid and serious consequences of stroke, effective preventive treatment is of utmost importance to reduce disability and improve survival in older adults with AF. Senior care pharmacists are in a critical position to improve stroke prevention in elderly patients with atrial fibrillation. However, our needs assessment reveals that senior care pharmacists face many challenges in ensuring that these patients receive optimal anticoagulation therapy.
Senior care pharmacists have the opportunity to reduce the risk of stroke in patients with AF by expanding their ability to facilitate the optimal use of anticoagulation therapy in older adults with AF. Also, as data on new and emerging therapies become available, senior care pharmacists need to remain up to date in order to continue providing optimal care based on current evidence. The goal of this continuing education activity for senior care pharmacists is to expand their knowledge and skill in best practices related to stroke prevention in older adults with AF, ultimately reducing stroke-related disability, dementia, and death in this patient population.
This educational activity is designed to meet the needs of consultant and senior care pharmacists.
Upon completion of this educational activity, the participant should be able to:
Identify the major barriers that are causing patients with AF to receive suboptimal anticoagulation.
Determine when the risk for stroke in older adults with atrial fibrillation exceeds the risk for anticoagulation-associated bleeding.
Assess the comparative benefits and risks of anticoagulant therapy to prevent stroke in patients with atrial fibrillation.
Explain differences in the pharmacokinetic and pharmacodynamic profiles of new and emerging oral anticoagulants.
It is the policy of the ASCP to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Arora has no relevant financial relationships with any commercial interests to disclose.
Dr. Beier discloses that she serves on the speakerís bureau for Boehringer Ingelheim. Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-147-H01-P, has been assigned 1.25 Contact Hour (0.125 CEU).
Please view and complete the posttest questions and activity evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.
There is no fee to participate in this educational activity.
Commercial Support Statements
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.